|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects localization multiple interactions |
ISO |
Buthionine Sulfoximine affects the localization of ABCC1 protein mutant form [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to monomethylarsonous acid analog]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to methylarsine analog] |
CTD |
PMID:15180633 PMID:15473893 PMID:15581632 PMID:21918036 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ACIN1 protein |
CTD |
PMID:23736079 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ACTB mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Add3 |
adducin 3 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ADD3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Ethanol results in increased expression of ADH1 mRNA] |
CTD |
PMID:20705415 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of AIMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased phosphorylation of AKT1 protein] Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24449419 PMID:36343453 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of ALAD protein |
CTD |
PMID:21620807 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [1,2,4-trichlorobenzene results in increased activity of ALAS1 protein] |
CTD |
PMID:11996131 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of ALB mRNA |
CTD |
PMID:23288050 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ALDOA mRNA; Buthionine Sulfoximine results in increased expression of ALDOA protein |
CTD |
PMID:11841787 PMID:23736079 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of AMBP mRNA |
CTD |
PMID:23288050 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of APEX1 protein |
CTD |
PMID:23736079 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoh |
apolipoprotein H |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of APOH mRNA |
CTD |
PMID:23288050 |
|
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein |
CTD |
PMID:19850110 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ARNT protein |
CTD |
PMID:16880289 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ATP5F1B mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atxn1 |
ataxin 1 |
affects localization multiple interactions |
ISO |
Buthionine Sulfoximine affects the localization of ATXN1 protein mutant form Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form] |
CTD |
PMID:12893416 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of AXL mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of AZIN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein] |
CTD |
PMID:11341981 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Buthionine Sulfoximine results in decreased expression of BCL2 mRNA Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein] [Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein] Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA] |
CTD |
PMID:11341981 PMID:17989939 PMID:25410294 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of BMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CALR protein |
CTD |
PMID:23736079 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO EXP |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein]; Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in increased expression of CASP3 mRNA] [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate co-treated with Buthionine Sulfoximine] results in increased cleavage of CASP3 protein; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of and results in increased cleavage of CASP3 protein]; Buthionine Sulfoximine results in increased expression of and results in increased cleavage of CASP3 protein [Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [Vitamin K 3 results in increased activity of CASP3 protein] |
CTD |
PMID:10673743 PMID:15276415 PMID:15963344 PMID:16310883 PMID:17200146 PMID:17989939 PMID:20962031 PMID:25003661 PMID:25341683 PMID:27592447 PMID:33309544 PMID:35298964 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP4 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of CASP7 protein] |
CTD |
PMID:20962031 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein] |
CTD |
PMID:17145888 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein]; Glutathione inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein] |
CTD |
PMID:33309544 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in decreased activity of CAT protein Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in decreased abundance of Glutathione]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]] |
CTD |
PMID:21620807 PMID:21772021 PMID:26187465 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL11 mRNA |
CTD |
PMID:22407903 PMID:27421576 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CCL2 mRNA] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA] |
CTD |
PMID:22407903 PMID:26177832 PMID:31294483 PMID:35123994 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]] |
CTD |
PMID:11167962 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of CCND1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of CD36 protein [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CD36 mRNA promotes the reaction [Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; CD36 mRNA promotes the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein] |
CTD |
PMID:26187465 PMID:27358406 PMID:28263783 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd59b |
CD59b molecule |
increases mutagenesis |
ISO |
Buthionine Sulfoximine results in increased mutagenesis of CD59 gene |
CTD |
PMID:15033018 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of CD86 protein |
CTD |
PMID:20457211 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1A protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein] |
CTD |
PMID:17602960 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1B protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein] |
CTD |
PMID:17602960 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:25977998 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CHERP protein |
CTD |
PMID:23736079 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10498651 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of COL5A3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of COX4I1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased phosphorylation of STAT3 protein] promotes the reaction [CREBBP protein results in increased acetylation of STAT3 protein modified form] |
CTD |
PMID:19289167 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Cse1l |
chromosome segregation 1 like |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CSE1L protein |
CTD |
PMID:23736079 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CSF1 mRNA] |
CTD |
PMID:35123994 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in decreased expression of CXCL12 mRNA Buthionine Sulfoximine results in increased expression of CXCL12 mRNA Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CXCL12 mRNA] |
CTD |
PMID:15878706 PMID:35123994 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 PMID:31294483 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL1 mRNA; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of CXCL1 protein] |
CTD |
PMID:26149495 PMID:31294483 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of CXCR4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases activity |
ISO EXP |
Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA] Buthionine Sulfoximine results in decreased activity of CYP1A1 protein Buthionine Sulfoximine results in increased activity of CYP1A1 protein [Buthionine Sulfoximine co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; [Buthionine Sulfoximine co-treated with Cadmium Chloride] results in increased expression of CYP1A1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of CYP1A1 mRNA; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine promotes the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Buthionine Sulfoximine inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:9756946 PMID:16274885 PMID:16906435 PMID:18078826 PMID:19033395 PMID:21094198 PMID:26535918 PMID:27041069 PMID:29975444 PMID:30793600 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases response to substance multiple interactions |
ISO |
CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine; CYP2E1 results in increased susceptibility to Buthionine Sulfoximine Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]; Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin promotes the reaction [CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Buthionine Sulfoximine] |
CTD |
PMID:10498651 PMID:12086689 PMID:12566070 PMID:22486562 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione; Buthionine Sulfoximine promotes the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; neferine promotes the reaction [[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione] |
CTD |
PMID:25451576 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dab1 |
DAB adaptor protein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of DAB1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of DARS1 protein |
CTD |
PMID:23736079 |
|
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of DDIT3 protein] |
CTD |
PMID:17171638 PMID:25341683 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of DGAT2 mRNA |
CTD |
PMID:20482862 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases activity |
EXP |
Buthionine Sulfoximine results in increased activity of DIO3 protein |
CTD |
PMID:18420745 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of DLD protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions decreases expression |
EXP |
sulforaphane inhibits the reaction [Buthionine Sulfoximine results in decreased expression of DRD1 protein] |
CTD |
PMID:23876469 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ECH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of EEF1A1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of EEF1B2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein] |
CTD |
PMID:36343453 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of EGR1 mRNA] |
CTD |
PMID:19010381 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF1A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B subunit delta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF2B4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829
|
|
G |
Eif3g |
eukaryotic translation initiation factor 3, subunit G |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF3G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:19,429,728...19,433,760
Ensembl chr 8:19,429,643...19,433,808
|
|
G |
Esyt1 |
extended synaptotagmin 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ESYT1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:928,848...946,199
Ensembl chr 7:928,848...946,199
|
|
G |
Etf1 |
eukaryotic translation termination factor 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ETF1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr18:26,502,413...26,530,753
Ensembl chr18:26,504,080...26,530,810
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EZH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Copper deficiency results in increased expression of FAS mRNA] |
CTD |
PMID:9227460 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA |
CTD |
PMID:23986454 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of FKBP5 protein |
CTD |
PMID:23736079 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of FLT1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea] |
CTD |
PMID:12093470 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein] |
CTD |
PMID:19524604 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of FOS mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] |
CTD |
PMID:7743507 PMID:15520183 PMID:18449455 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOSL1 mRNA] Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of FOSL1 mRNA] |
CTD |
PMID:15520183 PMID:19010381 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of FOXP3 mRNA |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA] Buthionine Sulfoximine results in increased expression of FTH1 mRNA |
CTD |
PMID:15878706 PMID:16631525 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of G6PD mRNA |
CTD |
PMID:12717738 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions increases expression |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone binds to GAPDH protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone results in decreased activity of GAPDH protein] Buthionine Sulfoximine results in increased expression of GAPDH mRNA |
CTD |
PMID:15878706 PMID:21827172 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions decreases expression |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GATA3 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA Buthionine Sulfoximine results in decreased expression of GATA3 mRNA |
CTD |
PMID:22407903 PMID:23986454 PMID:26177832 PMID:27421576 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gc |
GC, vitamin D binding protein |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of GC mRNA |
CTD |
PMID:23288050 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity decreases expression increases expression multiple interactions decreases activity |
ISO EXP |
Buthionine Sulfoximine results in increased activity of GCLC protein Buthionine Sulfoximine results in decreased expression of GCLC protein Buthionine Sulfoximine results in increased expression of GCLC mRNA [Buthionine Sulfoximine results in decreased activity of GCLC protein] inhibits the reaction [indenoindole results in increased abundance of Glutathione]; [Buthionine Sulfoximine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione; [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in decreased susceptibility to naphthalene]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [naphthalene results in increased activity of GCLC protein]; Buthionine Sulfoximine promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of GCLC mRNA] Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; Buthionine Sulfoximine inhibits the reaction [GCLC results in decreased susceptibility to Cadmium Chloride]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in decreased expression of GCLC protein] [Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in increased chemical synthesis of gamma-glutamylcysteine]; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GCLC mRNA] |
CTD |
PMID:7955076 PMID:10900227 PMID:10915739 PMID:10978506 PMID:11019651 PMID:12433058 PMID:12805647 PMID:12967637 PMID:15115889 PMID:15707499 PMID:16288907 PMID:17724089 PMID:17980396 PMID:18449455 PMID:18556457 PMID:22864849 PMID:23585199 PMID:24964298 PMID:34036678 PMID:35123994 PMID:35298964 More...
|
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased expression of GCLM mRNA Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione] [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]] |
CTD |
PMID:10978506 PMID:17724089 PMID:19010381 PMID:22864849 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of GDF15 mRNA Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of GDF15 mRNA] |
CTD |
PMID:35123994 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of GDI2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased expression of GFAP protein |
CTD |
PMID:19850110 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [arsenite results in increased expression of GLRX protein] |
CTD |
PMID:36343453 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gmfb |
glia maturation factor, beta |
increases response to substance |
ISO |
GMFB protein results in increased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:12791701 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPI1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
[allyl sulfide co-treated with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate] inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein; [Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased expression of and results in increased activity of GPT protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein] [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]; Tranylcypromine inhibits the reaction [[Methimazole co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein] |
CTD |
PMID:15950962 PMID:26177832 PMID:27421576 PMID:29679711 PMID:30853469 PMID:34788025 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects activity multiple interactions |
ISO EXP |
Buthionine Sulfoximine affects the activity of GPX1 protein Buthionine Sulfoximine promotes the reaction [Microcystins analog results in increased expression of GPX1 mRNA] Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of GPX1 mRNA] |
CTD |
PMID:15707499 PMID:24964298 PMID:25341683 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPX2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPX3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Acrolein results in decreased expression of GPX4 mRNA] |
CTD |
PMID:33421550 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of GRB2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gsn |
gelsolin |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]] Buthionine Sulfoximine inhibits the reaction [arsenite results in increased activity of GSR protein] [Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in decreased expression of GSR mRNA]; Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased expression of GSR mRNA] |
CTD |
PMID:12967637 PMID:16288907 PMID:17119269 PMID:21772021 PMID:24634002 PMID:24964298 PMID:25410294 PMID:36343453 More...
|
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
decreases activity increases expression |
EXP |
Buthionine Sulfoximine results in decreased activity of GSS protein Buthionine Sulfoximine results in increased expression of GSS mRNA |
CTD |
PMID:10904027 PMID:10978506 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of GSTA1 mRNA] |
CTD |
PMID:9152014 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSTM1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSTM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [GSTP1 results in decreased susceptibility to Benzo(a)pyrene] Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GSTP1 mRNA] |
CTD |
PMID:19330882 PMID:24964298 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HADH mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hbs1l |
HBS1-like translational GTPase |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of HBS1L mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:16,092,529...16,170,082
Ensembl chr 1:16,092,547...16,170,074
|
|
G |
Hdgf |
heparin binding growth factor |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HDGF mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:173,370,147...173,379,756
Ensembl chr 2:173,370,465...173,379,747
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HGF protein |
CTD |
PMID:9763232 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HIF1A protein] Buthionine Sulfoximine results in increased activity of HIF1A protein |
CTD |
PMID:11641398 PMID:11841787 PMID:17658243 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein] |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgb2 |
high mobility group box 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HMGB2 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140 Ensembl chr 1:32,710,658...32,713,140
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
1-aminobenzotriazole inhibits the reaction [[Acetaminophen co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Butylated Hydroxyanisole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Diclofenac co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Butylated Hydroxyanisole results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA] Buthionine Sulfoximine results in increased expression of HMOX1 protein Buthionine Sulfoximine results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine results in increased expression of HMOX1 protein [Buthionine Sulfoximine co-treated with sulforaphane] results in increased expression of HMOX1 protein; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein] [6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[sodium arsenite co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 protein] |
CTD |
PMID:7626009 PMID:9152014 PMID:11841787 PMID:12763371 PMID:16274885 PMID:16631525 PMID:18078826 PMID:18227147 PMID:18332044 PMID:19683516 PMID:20888885 PMID:21971136 PMID:22659318 PMID:23585199 PMID:23876469 PMID:23939143 PMID:24401988 PMID:26177832 PMID:28263783 PMID:30497689 PMID:31294483 PMID:32741899 PMID:34036678 PMID:35123994 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects response to substance |
ISO |
HMOX2 affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:16181104 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HNRNPM protein |
CTD |
PMID:23736079 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HSP90AA1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HSPA4 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of HSPA5 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO EXP |
Buthionine Sulfoximine results in increased expression of HSPA8 mRNA |
CTD |
PMID:7626009 PMID:15707499 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein] [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of ICAM1 mRNA |
CTD |
PMID:11164475 PMID:20116392 PMID:20351055 PMID:29154782 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions |
EXP |
Buthionine Sulfoximine affects the reaction [ID2 protein binds to MYC promoter] |
CTD |
PMID:19289167 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA] |
CTD |
PMID:17213664 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Buthionine Sulfoximine promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA] |
CTD |
PMID:19339665 PMID:26177832 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] |
CTD |
PMID:12688424 PMID:19339665 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein |
CTD |
PMID:23986454 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA] |
CTD |
PMID:29154782 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [hydroxyethyl methacrylate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of IL1B protein] |
CTD |
PMID:11970852 PMID:12433058 PMID:23986454 PMID:26149495 PMID:26177832 PMID:28188892 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL4 protein; Buthionine Sulfoximine promotes the reaction [Methimazole results in increased expression of IL4 protein] |
CTD |
PMID:22407903 PMID:27421576 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased secretion of IL6 protein [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL6 protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA] |
CTD |
PMID:11970852 PMID:12433058 PMID:15601679 PMID:19339665 PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 PMID:31294483 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA] |
CTD |
PMID:17213664 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of JAK1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of JAK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases activity |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased activity of JUN protein]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] Buthionine Sulfoximine inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA] Buthionine Sulfoximine results in decreased activity of JUN protein |
CTD |
PMID:7626009 PMID:7743507 PMID:11341981 PMID:11841787 PMID:11849044 PMID:15520183 PMID:16259964 PMID:18449455 PMID:21825963 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUNB mRNA] |
CTD |
PMID:15520183 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
multiple interactions |
EXP |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein |
CTD |
PMID:16288907 |
|
NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
EXP |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein |
CTD |
PMID:16288907 |
|
NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione] |
CTD |
PMID:19608619 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [KLF4 results in decreased susceptibility to Cisplatin] |
CTD |
PMID:21833590 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein] |
CTD |
PMID:22486562 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of KPNB1 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased expression of LCN2 mRNA [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA] Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of LCN2 mRNA] |
CTD |
PMID:23939143 PMID:29154782 PMID:29679711 PMID:30853469 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of LEF1 protein |
CTD |
PMID:27421576 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lrpprc |
leucine-rich pentatricopeptide repeat containing |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of LRPPRC protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of MAP1LC3B protein; Buthionine Sulfoximine results in increased expression of MAP1LC3B protein modified form Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein]; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in increased expression of MAP1LC3B protein] |
CTD |
PMID:34580807 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK1 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein] [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK1 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 PMID:31860779 PMID:34580807 PMID:36343453 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
decreases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA Sodium Selenite inhibits the reaction [Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA] |
CTD |
PMID:17989939 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Buthionine Sulfoximine results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:17191120 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK3 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein] [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK3 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein; Cadmium Chloride promotes the reaction [Buthionine Sulfoximine results in decreased expression of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 PMID:31860779 PMID:34580807 PMID:36343453 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[antimony trioxide co-treated with Buthionine Sulfoximine] results in decreased expression of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [antimony trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:14701702 PMID:16112521 PMID:36343453 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
decreases phosphorylation |
ISO |
Buthionine Sulfoximine results in decreased phosphorylation of MAPK9 protein |
CTD |
PMID:17191120 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in increased phosphorylation of MAPT protein |
CTD |
PMID:19850110 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mars1 |
methionyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of MARS1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
|
|
G |
Mb |
myoglobin |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:29679711 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of MEF2A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions decreases activity |
ISO |
Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin] Buthionine Sulfoximine results in decreased activity of MGMT protein |
CTD |
PMID:16039682 PMID:16950796 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir101-2 |
microRNA 101-2 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:226,860,371...226,860,467
Ensembl chr 1:226,860,371...226,860,467
|
|
G |
Mir106b |
microRNA 106b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR106B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425
|
|
G |
Mir127 |
microRNA 127 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR127 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:128,546,215...128,546,311
Ensembl chr 6:128,546,215...128,546,311
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA |
CTD |
PMID:28263783 PMID:29679711 PMID:30853469 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir136 |
microRNA 136 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR136 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:128,549,096...128,549,177
Ensembl chr 6:128,549,096...128,549,177
|
|
G |
Mir137 |
microRNA 137 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR137 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 2:206,480,881...206,480,982
Ensembl chr 2:206,480,884...206,480,985
|
|
G |
Mir138-1 |
microRNA 138-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR138-1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:122,300,966...122,301,064
Ensembl chr 8:122,300,966...122,301,064
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR141 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir148b |
microRNA 148b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR148B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494
|
|
G |
Mir151 |
microRNA 151 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR151 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 7:105,172,377...105,172,473
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR184 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mir187 |
microRNA 187 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR187 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR187 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr18:15,731,194...15,731,297
Ensembl chr18:15,731,194...15,731,297
|
|
G |
Mir188 |
microRNA 188 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR188 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:15,247,715...15,247,794
Ensembl chr X:15,247,715...15,247,794
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR190A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mir19a |
microRNA 19a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR19A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir200a |
microRNA 200a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR200A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 5:166,648,494...166,648,582
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA |
CTD |
PMID:28263783 PMID:29679711 PMID:30853469 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mir20b |
microRNA 20b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR20B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282
|
|
G |
Mir210 |
microRNA 210 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR210 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:196,326,343...196,326,452
Ensembl chr 1:196,326,337...196,326,454
|
|
G |
Mir211 |
microRNA 211 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR211 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:117,777,539...117,777,644
Ensembl chr 1:117,777,539...117,777,644
|
|
G |
Mir224 |
microRNA 224 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR224 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169
|
|
G |
Mir29b1 |
microRNA 29b-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29B-1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:59,650,987...59,651,067
Ensembl chr 4:59,650,986...59,651,067
|
|
G |
Mir322 |
microRNA 322 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR322 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR322 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688
|
|
G |
Mir324 |
microRNA 324 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR324 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr10:54,734,680...54,734,762
Ensembl chr10:54,734,678...54,734,766
|
|
G |
Mir328 |
microRNA 328 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR328 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849
|
|
G |
Mir337 |
microRNA 337 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR337 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:128,538,903...128,538,999
Ensembl chr 6:128,538,902...128,538,998
|
|
G |
Mir339 |
microRNA 339 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR339 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr12:15,277,546...15,277,641
Ensembl chr12:15,277,546...15,277,641
|
|
G |
Mir34b |
microRNA 34b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR34B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:51,410,244...51,410,327
Ensembl chr 8:51,410,244...51,410,327
|
|
G |
Mir361 |
microRNA 361 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR361 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:78,246,206...78,246,275
Ensembl chr X:78,246,206...78,246,275
|
|
G |
Mir375 |
microRNA 375 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR375 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 9:76,457,911...76,457,985
Ensembl chr 9:76,457,911...76,457,985
|
|
G |
Mir410 |
microRNA 410 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR410 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:128,758,358...128,758,433
Ensembl chr 6:128,758,354...128,758,434
|
|
G |
Mir449a |
microRNA 449a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR449A mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR449A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 2:44,670,714...44,670,804
Ensembl chr 2:44,670,714...44,670,804
|
|
G |
Mir450a1 |
microRNA 450a-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR450A1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:132,801,380...132,801,470
Ensembl chr X:132,801,380...132,801,470
|
|
G |
Mir455 |
microRNA 455 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR455 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390
|
|
G |
Mir671 |
microRNA 671 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR671 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:10,580,747...10,580,827
Ensembl chr 4:10,580,738...10,580,835
|
|
G |
Mir99a |
microRNA 99a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR99A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr11:16,200,443...16,200,523
Ensembl chr11:16,200,443...16,200,523
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] |
CTD |
PMID:10464329 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of MPO protein |
CTD |
PMID:26177832 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of MRPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129
|
|
G |
Mt1 |
metallothionein 1 |
increases expression increases activity multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased expression of MT1A mRNA Buthionine Sulfoximine results in increased activity of MT1 promoter Buthionine Sulfoximine promotes the reaction [Copper results in increased activity of MT1 promoter]; Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]; Dactinomycin inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]] Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MT1A mRNA] |
CTD |
PMID:7626009 PMID:8966720 PMID:9152014 PMID:14576086 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA |
CTD |
PMID:32741899 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions decreases response to substance |
ISO |
MTF1 results in decreased susceptibility to [Buthionine Sulfoximine co-treated with cadmium sulfate] MTF1 results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:16221973 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]] |
CTD |
PMID:26989453 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Buthionine Sulfoximine affects the reaction [ID2 protein binds to MYC promoter]; Buthionine Sulfoximine affects the reaction [SIN3A protein binds to MYC promoter]; Buthionine Sulfoximine promotes the reaction [STAT3 protein modified form binds to MYC promoter] |
CTD |
PMID:19289167 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of NARS1 protein |
CTD |
PMID:23736079 |
|
NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622
|
|
G |
Ndn |
necdin, MAGE family member |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NDN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:115,849,168...115,850,767
Ensembl chr 1:115,849,105...115,850,767
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NDUFA13 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726 Ensembl chr 7:19,526,565...19,535,726
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression affects expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [1,2-dihydroxynaphthalene analog results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein] Buthionine Sulfoximine results in increased expression of NFE2L2 protein [Buthionine Sulfoximine co-treated with sulforaphane] affects the expression of and affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of and affects the localization of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased expression of and affects the localization of NFE2L2 protein] Buthionine Sulfoximine affects the expression of NFE2L2 protein Buthionine Sulfoximine results in increased expression of NFE2L2 mRNA [6-formylindolo(3,2-b)carbazole co-treated with Buthionine Sulfoximine] results in increased expression of NFE2L2 mRNA; Buthionine Sulfoximine affects the localization of and results in increased activity of NFE2L2 protein; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Acrolein]; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforaphane] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [Dextromethorphan results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Acrolein]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to Chlorambucil]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforaphane results in decreased susceptibility to cumene hydroperoxide]] |
CTD |
PMID:17980396 PMID:18785192 PMID:19303893 PMID:19608619 PMID:20932822 PMID:20934533 PMID:21971136 PMID:23585199 PMID:23876469 PMID:24634002 PMID:25341683 PMID:25807370 PMID:34036678 PMID:34740715 PMID:36343453 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases expression |
EXP ISO |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA] |
CTD |
PMID:11970852 PMID:12433058 PMID:23472850 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions affects response to substance increases expression |
ISO |
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of NGF mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein] NGF protein affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:23472850 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of NLRP3 mRNA |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
[Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine] Buthionine Sulfoximine results in increased expression of NOS2 mRNA [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA] Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased expression of NOS2 mRNA] |
CTD |
PMID:7532384 PMID:9826428 PMID:16259964 PMID:16933320 PMID:23939143 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of NPC1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased activity of NQO1 protein Buthionine Sulfoximine results in increased expression of NQO1 mRNA Buthionine Sulfoximine results in increased expression of NQO1 mRNA; Buthionine Sulfoximine results in increased expression of NQO1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of NQO1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA] [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased activity of NQO1 protein; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased expression of NQO1 mRNA; [Tetrachlorodibenzodioxin co-treated with chromium trioxide co-treated with Buthionine Sulfoximine] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine inhibits the reaction [chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [[Benzene co-treated with Toluene] results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Benzene results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of NQO1 mRNA] [Buthionine Sulfoximine co-treated with Endosulfan] results in increased expression of NQO1 mRNA; [Buthionine Sulfoximine co-treated with sulforaphane] results in increased expression of NQO1 protein; Buthionine Sulfoximine promotes the reaction [Methylcholanthrene results in increased activity of NQO1 protein]; Methylcholanthrene promotes the reaction [Buthionine Sulfoximine results in increased activity of NQO1 protein] |
CTD |
PMID:16274885 PMID:16906435 PMID:18752316 PMID:20079720 PMID:21971136 PMID:22146149 PMID:23876469 PMID:25341683 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NR2F2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]; Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein] |
CTD |
PMID:23472850 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ODC1 protein |
CTD |
PMID:9763232 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions affects response to substance |
ISO |
Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA] OGG1 protein affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:32585298 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ORM1 mRNA; Buthionine Sulfoximine results in increased expression of ORM1 protein |
CTD |
PMID:11841787 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of P4HA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of PARP1 protein]; Buthionine Sulfoximine promotes the reaction [wedelolactone results in increased cleavage of PARP1 protein] |
CTD |
PMID:20962031 PMID:22733624 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP |
Buthionine Sulfoximine results in increased expression of PCK1 mRNA SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA] |
CTD |
PMID:16960379 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP ISO |
Buthionine Sulfoximine results in increased expression of PCNA protein Buthionine Sulfoximine results in increased expression of PCNA mRNA |
CTD |
PMID:9763232 PMID:15707499 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB mRNA]]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB protein]] |
CTD |
PMID:23392711 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PDIA3 protein |
CTD |
PMID:23736079 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PDK1 protein] |
CTD |
PMID:17171638 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pfas |
phosphoribosylformylglycinamidine synthase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PFAS protein |
CTD |
PMID:23736079 |
|
NCBI chr10:53,690,301...53,711,811
Ensembl chr10:53,691,626...53,708,420
|
|
G |
Phtf1 |
putative homeodomain transcription factor 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PHTF1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:191,470,849...191,537,399
Ensembl chr 2:191,473,130...191,512,078
|
|
G |
Plxna3 |
plexin A3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PLXNA3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:152,115,699...152,131,608
Ensembl chr X:152,115,819...152,131,603
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; S-ethyl glutathione inhibits the reaction [Buthionine Sulfoximine results in increased expression of PPARG mRNA] Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG protein] |
CTD |
PMID:17602960 PMID:21520053 PMID:27358406 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1g |
protein phosphatase, Mg2+/Mn2+ dependent, 1G |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PPM1G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:25,153,556...25,173,763
Ensembl chr 6:25,153,556...25,173,761
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PPP3CA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PPP5C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression affects expression |
ISO |
Buthionine Sulfoximine results in increased expression of PRDX1 mRNA Buthionine Sulfoximine affects the expression of PRDX1 mRNA |
CTD |
PMID:9506838 PMID:15707499 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prim2 |
DNA primase subunit 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PRIM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030
|
|
G |
Prkca |
protein kinase C, alpha |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of PRKCA protein |
CTD |
PMID:11118818 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of PRKCB protein |
CTD |
PMID:11118818 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PRKCD protein] Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCD protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein] |
CTD |
PMID:11118818 PMID:17171638 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCE protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein] |
CTD |
PMID:11118818 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prpf19 |
pre-mRNA processing factor 19 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PRPF19 protein |
CTD |
PMID:23736079 |
|
NCBI chr 1:207,541,582...207,552,664
Ensembl chr 1:207,541,595...207,552,662
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein] |
CTD |
PMID:24449419 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of PTGS2 mRNA] |
CTD |
PMID:23376440 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PTK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases oxidation |
EXP |
Buthionine Sulfoximine results in increased oxidation of PTPN1 protein |
CTD |
PMID:20482862 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PTTG1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of RBBP6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of REL protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [cinnamaldehyde results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased phosphorylation of RELA protein] Buthionine Sulfoximine results in increased expression of RELA protein Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] Buthionine Sulfoximine affects the reaction [Dextromethorphan affects the activity of RELA protein]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased expression of RELA mRNA] Buthionine Sulfoximine results in increased expression of RELA mRNA |
CTD |
PMID:11970852 PMID:12433058 PMID:18449455 PMID:20116392 PMID:20351055 PMID:23876469 PMID:34740715 PMID:36343453 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELB protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of RORC mRNA |
CTD |
PMID:26177832 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rpl10a |
ribosomal protein L10A |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL10A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357 Ensembl chr 9:6,385,823...6,391,357
|
|
G |
Rpl12 |
ribosomal protein L12 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:16,264,269...16,266,645
Ensembl chr 3:16,264,251...16,266,642
|
|
G |
Rpl3 |
ribosomal protein L3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of RPL3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:111,622,255...111,627,640
Ensembl chr 7:111,621,610...111,636,468
|
|
G |
Rpl6 |
ribosomal protein L6 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL6 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rpl8 |
ribosomal protein L8 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482 Ensembl chr 3:108,622,324...108,628,482
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPLP0 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPLP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
|
|
G |
Rps12 |
ribosomal protein S12 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps14 |
ribosomal protein S14 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS14 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:54,227,854...54,232,638
Ensembl chr18:54,227,854...54,233,166
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS15 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450 Ensembl chr 7:9,416,004...9,417,450
|
|
G |
Rps20 |
ribosomal protein S20 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS20 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:16,819,095...16,820,476
Ensembl chr 5:16,819,304...16,820,475 Ensembl chr 9:16,819,304...16,820,475 Ensembl chr 3:16,819,304...16,820,475 Ensembl chr 5:16,819,304...16,820,475
|
|
G |
Rps26 |
ribosomal protein S26 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS26 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:1,057,332...1,058,882
Ensembl chr X:107,822,178...107,822,525
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145 Ensembl chr 5:45,223,980...45,271,145
|
|
G |
Rps8 |
ribosomal protein S8 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:130,630,362...130,632,932
Ensembl chr 5:130,629,716...130,633,268
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:28263783 PMID:30853469 PMID:31294483 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of S100A9 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:28263783 PMID:29154782 PMID:30853469 PMID:31294483 More...
|
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Scarna15 |
small Cajal body-specific RNA 15 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1839 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:135,484,620...135,484,683
Ensembl chr 1:135,484,559...135,484,685 Ensembl chr 1:135,484,559...135,484,685
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA] |
CTD |
PMID:21971136 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selenow |
selenoprotein W |
decreases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in decreased expression of SELENOW mRNA [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased expression of SELENOW mRNA |
CTD |
PMID:15823556 |
|
NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724 Ensembl chr 1:76,598,779...76,604,724
|
|
G |
Serpina3n |
serpin family A member 3N |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SESN2 protein |
CTD |
PMID:31323261 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Shank3 |
SH3 and multiple ankyrin repeat domains 3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SHANK3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:120,568,707...120,630,796
Ensembl chr 7:120,570,402...120,630,374
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SIAH2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
|
|
G |
Sin3a |
SIN3 transcription regulator family member A |
multiple interactions |
EXP |
Buthionine Sulfoximine affects the reaction [SIN3A protein binds to MYC promoter] |
CTD |
PMID:19289167 |
|
NCBI chr 8:57,481,539...57,536,195
Ensembl chr 8:57,481,573...57,536,192
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [SLC31A1 protein results in increased import of Copper]; Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]; glutathione diethyl ester inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]] |
CTD |
PMID:23426973 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in decreased activity of SLC9A3 protein] |
CTD |
PMID:23876469 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Snca |
synuclein alpha |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SNCA protein |
CTD |
PMID:15114628 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Snta1 |
syntrophin, alpha 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SNTA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:142,876,285...142,906,737
Ensembl chr 3:142,876,296...142,906,709
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SOD1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases response to substance |
ISO |
[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA] SOD2 protein results in increased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:8877099 PMID:10464329 PMID:15130278 PMID:32585298 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased secretion of SORD protein] |
CTD |
PMID:12763371 |
|
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 protein |
CTD |
PMID:27421576 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Sp1 |
Sp1 transcription factor |
increases activity multiple interactions |
ISO |
Buthionine Sulfoximine results in increased activity of SP1 protein mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP1 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp3 |
Sp3 transcription factor |
multiple interactions increases activity |
ISO |
mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP3 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SPP1 mRNA |
CTD |
PMID:15707499 PMID:15878706 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20482862 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Metformin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein]]; Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein] |
CTD |
PMID:29499335 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SRXN1 protein |
CTD |
PMID:27358234 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases activity multiple interactions increases phosphorylation increases expression |
EXP ISO |
Buthionine Sulfoximine results in increased activity of STAT3 protein [Buthionine Sulfoximine results in increased phosphorylation of STAT3 protein] promotes the reaction [CREBBP protein results in increased acetylation of STAT3 protein modified form]; Buthionine Sulfoximine promotes the reaction [STAT3 protein modified form binds to MYC promoter] [Troglitazone co-treated with Buthionine Sulfoximine] results in increased phosphorylation of STAT3 protein Buthionine Sulfoximine results in increased expression of STAT3 mRNA |
CTD |
PMID:11841787 PMID:19289167 PMID:31294483 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Syn1 |
synapsin I |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SYN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Syp |
synaptophysin |
multiple interactions |
EXP |
(22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate inhibits the reaction [[ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein]; [ferrous sulfate co-treated with APP protein alternative form co-treated with Buthionine Sulfoximine] results in decreased expression of SYP protein |
CTD |
PMID:19850110 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tbca |
tubulin folding cofactor A |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TBCA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:26,011,714...26,065,909
Ensembl chr 2:26,011,795...26,065,907
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein] |
CTD |
PMID:36343453 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of THRSP mRNA |
CTD |
PMID:20482862 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tinf2 |
TERF1 interacting nuclear factor 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TINF2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:29,170,663...29,178,015
Ensembl chr15:29,170,652...29,176,984
|
|
G |
Tle5 |
TLE family member 5, transcriptional modulator |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TLE5 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein] |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796
|
|
G |
Tmsb10 |
thymosin, beta 10 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TMSB10 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein]; [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamaldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA] [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of TNF mRNA; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TNF mRNA; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine] |
CTD |
PMID:7532384 PMID:11167962 PMID:11970852 PMID:12433058 PMID:15601679 PMID:16271621 PMID:18755394 PMID:20116392 PMID:20351055 PMID:21971136 PMID:26177832 PMID:28263783 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top2b |
DNA topoisomerase II beta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of TOP2B mRNA |
CTD |
PMID:15707499 |
|
NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein |
CTD |
PMID:12807757 PMID:25410294 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of TPI1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of TRAP1 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein] |
CTD |
PMID:33309544 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions |
EXP |
[Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine; [Ruthenium Red results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:20064552 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of TXN1 mRNA Buthionine Sulfoximine inhibits the reaction [arsenite results in increased expression of TXN protein] NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA] |
CTD |
PMID:23472850 PMID:36343453 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions increases response to substance increases expression |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenite results in increased activity of TXNRD1 protein]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased activity of TXNRD1 protein] TXNRD1 gene mutant form results in increased susceptibility to Buthionine Sulfoximine Buthionine Sulfoximine results in increased expression of TXNRD1 mRNA [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of TXNRD1 protein |
CTD |
PMID:12663510 PMID:16288907 PMID:19010381 PMID:24853413 PMID:36343453 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of U2AF2 protein |
CTD |
PMID:23736079 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Ubc |
ubiquitin C |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of UBC mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
[[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] [Troglitazone co-treated with Buthionine Sulfoximine] results in increased expression of VCAM1 mRNA |
CTD |
PMID:16271621 PMID:21971136 PMID:31294483 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA] |
CTD |
PMID:11641398 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vps26c |
VPS26 endosomal protein sorting factor C |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of VPS26C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:33,813,467...33,841,883
Ensembl chr11:33,792,389...33,841,447
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349
|
|
G |
Zfp422 |
zinc finger protein 422 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ZFP422 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:149,885,805...149,893,287
Ensembl chr 4:149,885,600...149,893,257
|
|